Immatics (NASDAQ:IMTX) Short Interest Up 6.2% in March

Immatics (NASDAQ:IMTX) saw a large growth in short interest in March. As of March 31st, there was short interest totalling 8,910,000 shares, a growth of 6.2% from the March 15th total of 8,390,000 shares. Based on an average daily volume of 526,500 shares, the short-interest ratio is currently 16.9 days.

Institutional Investors Weigh In On Immatics

Institutional investors and hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its stake in shares of Immatics by 150.5% during the 1st quarter. JPMorgan Chase & Co. now owns 202,640 shares of the company’s stock worth $1,619,000 after purchasing an additional 121,754 shares during the last quarter. BlackRock Inc. acquired a new position in Immatics in the 1st quarter valued at $27,000. Nantahala Capital Management LLC lifted its stake in shares of Immatics by 0.9% during the 1st quarter. Nantahala Capital Management LLC now owns 2,944,659 shares of the company’s stock worth $23,528,000 after purchasing an additional 25,997 shares during the period. Lazard Asset Management LLC acquired a new stake in shares of Immatics during the first quarter worth $84,000. Finally, Renaissance Technologies LLC grew its position in shares of Immatics by 17.5% in the first quarter. Renaissance Technologies LLC now owns 61,798 shares of the company’s stock valued at $494,000 after purchasing an additional 9,198 shares during the period. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Immatics Trading Down 1.4 %

IMTX stock opened at $10.23 on Thursday. Immatics has a 52 week low of $6.46 and a 52 week high of $13.16. The company has a market cap of $866.05 million, a P/E ratio of -7.87 and a beta of 0.67. The company’s 50-day moving average price is $11.50 and its 200 day moving average price is $10.44.

Immatics (NASDAQ:IMTX) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. The business had revenue of $17.14 million during the quarter, compared to analysts’ expectations of $11.78 million. Immatics had a negative return on equity of 43.58% and a negative net margin of 179.67%. On average, equities research analysts expect that Immatics will post -1.44 earnings per share for the current year.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.